Amy Stark to Cisplatin
This is a "connection" page, showing publications Amy Stark has written about Cisplatin.
Connection Strength
1.017
-
Identification of Novel Protein Expression Changes Following Cisplatin Treatment and Application to Combination Therapy. J Proteome Res. 2017 11 03; 16(11):4227-4236.
Score: 0.459
-
Functional consequences of PRPF39 on distant genes and cisplatin sensitivity. Hum Mol Genet. 2012 Oct 01; 21(19):4348-55.
Score: 0.319
-
Protein quantitative trait loci identify novel candidates modulating cellular response to chemotherapy. PLoS Genet. 2014 Apr; 10(4):e1004192.
Score: 0.090
-
Comprehensive evaluation of the contribution of X chromosome genes to platinum sensitivity. Mol Cancer Ther. 2011 Mar; 10(3):472-80.
Score: 0.072
-
EPS8 inhibition increases cisplatin sensitivity in lung cancer cells. PLoS One. 2013; 8(12):e82220.
Score: 0.022
-
Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J. 2013 Feb; 13(1):35-43.
Score: 0.019
-
Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans. PLoS One. 2011; 6(7):e21920.
Score: 0.019
-
Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants. Pharmacogenet Genomics. 2010 May; 20(5):327-37.
Score: 0.017